Regional Activation of Leukocytes in Coronary Artery Disease (REAL-CAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02376738|
Recruitment Status : Completed
First Posted : March 3, 2015
Last Update Posted : March 3, 2015
|Condition or disease|
|Inflammation Coronary Artery Disease|
- The primary aim of REAL CAD is to determine regional differences of leukocyte activation in different vascular beds in vivo.
- The secondary aim is to investigate differences in leukocyte activation between diabetic and CAD subjects and patients suffering from both.
- The third aim is to investigate the relationship between complement components, triglycerides and leukocyte activation markers in order to gain more insight into the causative processes leading to activation of leukocytes.
- The fourth aim is to get more insight in the MBL genotypes and serum levels of CAD and/or diabetic patients and the 'healthy' groups included in our study.
|Study Type :||Observational|
|Actual Enrollment :||97 participants|
|Official Title:||Regional Activation of Leukocytes in Coronary Artery Disease|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
- Assess the level of leukocyte activation in different vascular beds, by measuring monocyte CD11b and neutrophil CD11b and CD66b in blood obtained from the left and right coronary artery, the abdominal aorta, the femoral artery and a peripheral vein [ Time Frame: Baseline ]
- Investigate differences in leukocyte activation between patients with and without diabetes mellitus or coronary artery disease by comparing the level of monocyte CD11b and neutrophil CD11b and CD66b [ Time Frame: Baseline ]
- To investigate the predictive value of leukocyte activation markers CD11b and CD66b in different vascular regions in the prediction of future coronary events, by measuring these markers at baseline [ Time Frame: 6 years follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02376738
|Sint Franciscus Gasthuis|
|Rotterdam, Zuid-Holland, Netherlands, 3045 PM|
|Sint Franciscus Gasthuis|
|Rotterdam, Zuid-Holland, Netherlands, 3045PM|
|Principal Investigator:||Manuel Castro Cabezas, MD PhD||Sint Franciscus Gasthuis|